BioGaia Biologics

Peter Rothschild and Jan Annwall acquire the rights for the probiotic use of Lactobacillus reuteri and establish the company BioGaia Biologics. The duo also acquires the laboratory operations in Raleigh, USA. The focus is on reducing the need for antibiotics in animal feed. There is also an awakening interest in human health and so-called functional foods. The first brand with BioGaia products is BRA milk and fermented mil006B


Functional food

 Launch of the first functional food product containing BioGaia probiotics


First patent

First patent on Lactobacillus reuteri granted


ICA acquires the BRA trademark

ICA acquires the BRA trademark and concept


First clinical trial

First Lactobacillus reuteri clinical trial in humans published



Introduction on IM, Innovationsmarknaden


Multi Ferm

The fermentation facility Multi Ferm in Lund is acquired and becomes BioGaia Fermentation AB. The aim is to gain greater knowledge about the fermentation process and how to extend the shelf life of the bacterial cultures. The unique LifeTop cap bottle closure was developed.* Launch of the first probiotic fresh juice and fresh cheese with Lactobacillus reuteri



Introduction on the O-list on the Stockholm Stock Exchange


First tablet in the world

BioGaia launches the first probiotic chewable tablet in the world


Probiotic infant formula

The first probiotic infant formula with Lactobacillus reuteri is introduced to the market.*Patent for BioGaia Probiotic Straw (former LifeTop Straw), the first probiotic drinking straw, is approved. Price pressure and daunting regulatory hurdles lead to a decision to abandon activities in the animal health area. The main focus is now on probiotic dietary supplements for humans



BioGaia Fermentation AB is sold at a profit. The BioGaia has acquired the necessary knowledge and can retain parts of the staff in a production and development unit that becomes the current BioGaia Lund. TwoPac (50 per cent-owned) in Eslöv is formed together with a couple of entrepreneurs to develop a concept for reuteri-containing straws. Launch of the first probiotic straw in the world


The world’s first probiotic drops

The world’s first probiotic drops for infants are launched. Over one billion daily doses of  Lactobacillus reuteri sold globally*


Oral health products

Launch of the first probiotic oral health products for adults.


BioGaia brand

Launch of the BioGaia brand
. The first year that the company makes a profit.


Reduce crying time

Lactobacillus reuteri Protectis shown to significantly reduce crying time in infants with colic


Over 50 studies

Over 50 studies with Lactobacillus reuteri in more than 4,000 subjects. Global agreement with Nestlé Nutrition for infant baby formula. BioGaia products sold in more than 40 countries. CapAble is founded and is responsible for development of caps with probiotics


Probiotic oral rehydration solution

Launch of the BioGaia probiotic oral rehydration solution (ORS) containing Lactobacillus reuteri Protectis and zinc.* Net sales exceeds SEK 200 million


Celebrates 20 years

Three billion doses sold globally. 80 studies carried out on over 5,000 individuals. BioGaia’s products sold in more than 60 countries. BioGaia celebrates 20 years as a successful probiotics company


New products

Launch of oral health drops, drops with Vitamin D and digestive health tablet with strawberry flavour. Drops that can be stored at room temperature are also launched. 92 clinical studies using BioGaia’s human strains of Lactobacillus reuteri performed in more than 7,700 individuals of all ages. Results published in 55 articles in scientific journals. Net sales of over SEK 300 million. BioGaia’s 50 per cent-owned subsidiary TwoPac builds a new production facility in Eslöv to meet demand for increased volumes. BioGaia goes from listed as Small Cap to Mid Cap at NASDAQ OMX Nordic Exchange Stockholm


Collaboration with Nestlé

BioGaia extends and deepens its collaboration with Nestlé. TwoPac’s new production facility is completed. 108 clinical studies using BioGaia’s human strains of Lactobacillus reuteri performed in more than 8,600 individuals of all ages. Results published in 69 articles in scientific journals and five doctoral theses


IBT + TwoPac

BioGaia aquires the remaining 50 per cent of TwoPac. Infant Bacterial Therapeutics is formed and is responsible for development of a drug for premature infants



BioGaia invests in the Swedish research company MetaboGen


Good Manufacturing Practice

BioGaia’s production facility TwoPac obtains GMP (Good Manufacturing Practice) certification


IBT + Easy Dropper

Distribution of IBT:s shares to BioGaia’s shareholders. IBT is listed on First North. Launch of the packaging format Easy Dropper